The effect and optimal dose of sufentanil in reducing injection pain of microemulsion propofol
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Chung, D.H. | - |
dc.contributor.author | Kim, N.S. | - |
dc.contributor.author | Lee, M.K. | - |
dc.contributor.author | Jo, H.-K. | - |
dc.date.accessioned | 2021-09-07T20:21:08Z | - |
dc.date.available | 2021-09-07T20:21:08Z | - |
dc.date.created | 2021-06-17 | - |
dc.date.issued | 2011 | - |
dc.identifier.issn | 2005-6419 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/114610 | - |
dc.description.abstract | Background: Propofol is used as an induction and maintenance agent for general anesthesia but it can cause adverse reactions like hyperlipidemia, growth of microorganisms, and pulmonary embolisms. Microemulsion propofol was developed to avoid these side effects but incidence and severity of pain on injection is higher than with lipid emulsion propofol. We aimed to compare the effects of sufentanil in analgesic doses for reducing the injection pain of microemulsion propofol. Methods: The candidates included eighty patients, 19-60 years old and ASA I-II. They were randomly classified into four groups and pretreated with normal saline, sufentanil 0.1 μg/kg, 0.2 μg/kg or 0.3 μg/kg before injection of microemulsion propofol. Five minutes after receiving pretreatment drug, 2 mg/kg of microemulsion propofol was injected and VAS was recorded. Results: There were no significant differences in the incidence of injection pain among the groups. Severity of injection pain was significantly lower in the sufentanil 0.3 μg/kg group than normal saline and sufentanil 0.1 μg/kg group. Significant differences in blood pressure and heart rate were observed in sufentanil groups only after endotracheal intubation. One patient each in sufentanil 0.1 μg/kg and 0.3 μg/kg group experienced mild cough, one from sufentanil 0.3 μg/kg group experienced dizziness and another showed signs of hypoxia. One patient each in normal saline and sufentanil 0.1 μg/kg group showed clinical symptoms of phlebitis in the injection area. Conclusions: Pretreatment with sufentanil 0.3 μg/kg reduced the severity of microemulsion propofol injection pain without increasing arterial blood pressure and heart rate after endotracheal intubation. Copyright © the Korean Society of Anesthesiologists, 2011. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.subject | aquafol | - |
dc.subject | propofol | - |
dc.subject | sodium chloride | - |
dc.subject | sufentanil | - |
dc.subject | unclassified drug | - |
dc.subject | adult | - |
dc.subject | article | - |
dc.subject | blood pressure | - |
dc.subject | coughing | - |
dc.subject | diastolic blood pressure | - |
dc.subject | dizziness | - |
dc.subject | double blind procedure | - |
dc.subject | drug effect | - |
dc.subject | endotracheal intubation | - |
dc.subject | female | - |
dc.subject | heart rate | - |
dc.subject | human | - |
dc.subject | hypoxia | - |
dc.subject | injection pain | - |
dc.subject | injection site phlebitis | - |
dc.subject | major clinical study | - |
dc.subject | male | - |
dc.subject | microemulsion | - |
dc.subject | optimal drug dose | - |
dc.subject | oxygen saturation | - |
dc.subject | pain assessment | - |
dc.subject | randomized controlled trial | - |
dc.subject | systolic blood pressure | - |
dc.subject | visual analog scale | - |
dc.title | The effect and optimal dose of sufentanil in reducing injection pain of microemulsion propofol | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Kim, N.S. | - |
dc.contributor.affiliatedAuthor | Lee, M.K. | - |
dc.identifier.doi | 10.4097/kjae.2011.60.2.83 | - |
dc.identifier.scopusid | 2-s2.0-79952550646 | - |
dc.identifier.bibliographicCitation | Korean Journal of Anesthesiology, v.60, no.2, pp.83 - 89 | - |
dc.relation.isPartOf | Korean Journal of Anesthesiology | - |
dc.citation.title | Korean Journal of Anesthesiology | - |
dc.citation.volume | 60 | - |
dc.citation.number | 2 | - |
dc.citation.startPage | 83 | - |
dc.citation.endPage | 89 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.identifier.kciid | ART001527903 | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scopus | - |
dc.description.journalRegisteredClass | kci | - |
dc.subject.keywordPlus | aquafol | - |
dc.subject.keywordPlus | propofol | - |
dc.subject.keywordPlus | sodium chloride | - |
dc.subject.keywordPlus | sufentanil | - |
dc.subject.keywordPlus | unclassified drug | - |
dc.subject.keywordPlus | adult | - |
dc.subject.keywordPlus | article | - |
dc.subject.keywordPlus | blood pressure | - |
dc.subject.keywordPlus | coughing | - |
dc.subject.keywordPlus | diastolic blood pressure | - |
dc.subject.keywordPlus | dizziness | - |
dc.subject.keywordPlus | double blind procedure | - |
dc.subject.keywordPlus | drug effect | - |
dc.subject.keywordPlus | endotracheal intubation | - |
dc.subject.keywordPlus | female | - |
dc.subject.keywordPlus | heart rate | - |
dc.subject.keywordPlus | human | - |
dc.subject.keywordPlus | hypoxia | - |
dc.subject.keywordPlus | injection pain | - |
dc.subject.keywordPlus | injection site phlebitis | - |
dc.subject.keywordPlus | major clinical study | - |
dc.subject.keywordPlus | male | - |
dc.subject.keywordPlus | microemulsion | - |
dc.subject.keywordPlus | optimal drug dose | - |
dc.subject.keywordPlus | oxygen saturation | - |
dc.subject.keywordPlus | pain assessment | - |
dc.subject.keywordPlus | randomized controlled trial | - |
dc.subject.keywordPlus | systolic blood pressure | - |
dc.subject.keywordPlus | visual analog scale | - |
dc.subject.keywordAuthor | Injection pain | - |
dc.subject.keywordAuthor | Microemulsion propofol | - |
dc.subject.keywordAuthor | Sufentanil | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.